Contact Us

CleanCap® mRNA capping technology

Accelerate therapeutic and vaccine development with an effective mRNA capping strategy

The 5’ cap structure is integral to the stability, expression, and immunogenicity of an mRNA product, but generating a synthetic cap can present manufacturing challenges and inefficiencies. The TriLink® patented CleanCap® technology offers:

  • One-pot co-transcriptional capping strategy
  • mRNA with an optimal Cap 1 structure
  • Over 95% capping efficiency

Co-transcriptional capping with CleanCap® technology overcomes the limitations of legacy capping methods, helping you bring your mRNA vaccine or therapeutic to market faster.

CleanCap_Chart_720x575

How does the CleanCap® technology work?

Learn about mRNA capping, co-transcriptional capping, and benefits of TriLink's patented CleanCap® capping technology.

Streamline mRNA manufacturing processes and reduce costs

As momentum grows in the mRNA therapeutic and vaccine pipeline, development timelines are critical in the race to reach the market. Leveraging TriLink's patented CleanCap® technology co-transcriptional capping solution, you can:

  • Cut mRNA therapeutic production processes by nearly one week.
  • Reduce overall manufacturing costs 20-40% lower than other capping methods.

By streamlining manufacturing, CleanCap® technology helps to ensure your mRNA program meets key development deadlines and cost-saving targets, increasing your likelihood of success in the path to the clinic.

Estimates_Graphics_1_720x720_121224
Estimates_Graphics_2_720x720_121224

White paper on the economics of mRNA capping strategies

Choose the right CleanCap® analog for your application

TriLink offers a robust portfolio of patented CleanCap® cap analogs for use in the discovery or GMP manufacturing of vaccines, cell therapies, gene replacement therapies, and more, ensuring an optimal mRNA capping strategy to help maximize mRNA potency and subsequent protein expression.

Comparisons of CleanCap® analogs

 CleanCap ® M6 analog CleanCap ® AG 3’ OMe analog CleanCap ® AG analog CleanCap ® AU analog
Structure
ApplicationmRNAmRNAmRNASelf-amplifying RNA
Cap modification(s)
  • 2’ O-methylation on the first base (Cap 1)
  • 3’ O-methylation on m7G
  • m6A modification
  • 2’ O-methylation on the first base (Cap 1)
  • 3’ O-methylation on m7G
  • 2’ O-methylation on the first base (Cap 1)
  • 2’ O-methylation on the first base (Cap 1)
  • Alphavirus 5’ cap
Capping efficiency> 95%> 95%> 95%> 95%
Protein expressionHighestHigherHighHigh
 Learn moreLearn moreLearn moreLearn more

Related products and services

Novasep_Hipersep

Modified NTPs

Our extensive modified nucleoside triphosphates, available in RUO- and GMP-grade, provide quality and flexibility in your RNA application.

Largescale_NTP_Synthesis

N1-methylpseudouridine-5’-triphosphate

This popular modified NTP, available in both GMP- and RUO-grade, is for incorporation into mRNA using in vitro transcription.

Akta_ready

mRNA synthesis and manufacturing services

Our manufacturing processes are fully customizable and scalable to support your needs for discovery, preclinical, and clinical projects.

Have questions about the CleanCap® technology? Discuss with one of our experts.

Complete the form below and our Business Development team will contact you shortly.

CleanCap Inquiry

Clean Cap
Privacy policy
TriLink BioTechnologies does not sell or distribute your information to 3rd parties. For more information, please refer to our Privacy Policy.

White paper on the economics of mRNA capping strategies

Clean Cap
Privacy policy
TriLink BioTechnologies does not sell or distribute your information to 3rd parties. For more information, please refer to our Privacy Policy.